The findings that alteration of the substrate spectrum (cervical cancer), loss of E3 function (AS), and increased E3 function (Dup15q) of E6AP contribute to the development of distinct disorders indicate that expression and/or E3 activity of E6AP have to be tightly controlled. This evidence concerns the gene UBE3A and cervical carcinoma.